OncoMatch/Clinical Trials/NCT06713369

AZD5305 hADME in Patients With Advanced Solid Malignancies

Is NCT06713369 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Saruparib (AZD5305) and [14C]-AZD5305 microtracer for locally advanced or metastatic solid tumor.

Phase 1RecruitingAstraZenecaNCT06713369Data as of May 2026

Treatment: Saruparib (AZD5305) · [14C]-AZD5305 microtracer · [14C]-AZD5305 (therapeutic dose) — This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of \[14C\]-Saruparib in patients with advanced solid malignancies. This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable).

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: PARP inhibitor

Any prior treatment with a PARP inhibitor

Cannot have received: platinum-based chemotherapy

Any prior treatment with...platinum chemotherapy

Lab requirements

Blood counts

Adequate organ and marrow function as defined in the protocol

Kidney function

Adequate organ and marrow function as defined in the protocol

Liver function

Adequate organ and marrow function as defined in the protocol

Adequate organ and marrow function as defined in the protocol

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify